Government · 1 deal
Every published round Biomedical Translation Bridge took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Cincera Therapeutics | Grant | 2020 | $1m | Lead | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Companies Biomedical Translation Bridge has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Cincera Therapeutics | 2020, Grant | 1 | 1 |
Fund closes reported for Biomedical Translation Bridge, as distinct from the investments it has made.
Companies Biomedical Translation Bridge has backed that another company then bought. An exit for the holding, not a deal Biomedical Translation Bridge did.
Stories naming Biomedical Translation Bridge. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cincera Therapeutics has received a million-dollar Biomedical Translation Bridge grant to advance its Des-1 inhibitor drug for obesity-related metabolic diseases. The Monash and UniSA spin-out previously secured venture funding from the Medical Research Commercialisation Fund.